Company
Rising
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
13
5 still marketed
Novel approvals
4
Approvals since 2021
1
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Acetaminophen approved Jan 15, 2021
- Atropine Sulfate approved Priority reviewJul 18, 2014
- Extina approved Jun 12, 2007
- Astelin new use Feb 17, 2006
- Astelin new use Sep 15, 2000
- Astelin new use May 30, 2000
- Optivar approved May 22, 2000
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
- Sufenta Preservative Free Sufentanil Citrate · 1984
- Sublimaze Preservative Free Fentanyl Citrate · 1968
- Alfenta Alfentanil Hydrochloride · 1986
- Atropine Sulfate Atropine Sulfate · 2014
- Sulfamylon Mafenide Acetate · 1969
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.